Abstract 561P
Background
Introduction: Osimertinib (Osi) is the key standard therapy for patients (pts) with chemo-naive advanced non-small cell lung cancer (NSCLC) harboring sensitizing epidermal growth factor receptor (EGFR) mutations. However, many of cases treated with Osi experience the progressive disease (PD). Therefore, understanding first-line osimertinib resistance mechanisms is essential for future therapeutic strategies. Therefore, to clarify Osi resistance mechanisms, we proposed to analyze circulating tumor (ct) deoxyribonucleic acid (DNA) by the ultra-sensitive next-generation sequencing (NGS) method.
Methods
This trial is the multicenter prospective research, named ELUCIDATOR trial, and we prospectively collected ct-DNA samples before starting Osi as baseline and immediately after PD point. Then using these ct-DNA, we analyzed the Osi resistance by ultra-sensitive NGS. Acquired mechanisms of resistance were identified by comparing paired plasma samples at baseline and at PD in patients with and without detectable plasma EGFR mutation.
Results
188 pts were enrolled, 178 pts were included in the analyses, and 111 experienced PD and, among these,85 could analyze ct-DNA using NGS. Among 188 patients, 125 (66%) patients were female, 96 (51%) were EGFR exon 19 deletion mutation, and 109 (58%) were never smoker. New adaptive mutations or amplification (amp) at PD were MET amplification (amp) 4, cases, TP53 4, PIK3CA in 3, BRIMP3 2, BRAF 2, and APC 1 case. Furthermore, additional EGFR resistance mutations, such as C797S, were 1 case.
Conclusions
MET amp and PIK3CA mutation are the common resistance mechanisms of osimertinib PD, and the rate of additional EGFR resistance mutations is lower compared with prior studies.
Clinical trial identification
jRCTs031180051.
Editorial acknowledgement
Legal entity responsible for the study
National Hospital Organization, Japan.
Funding
National Hospital Organization, Japan. and AstraZeneca.
Disclosure
D. Harada: Financial Interests, Personal, Invited Speaker: Takeda, Eli Lilly, Chugai Pharmaceutical, AstraZeneca, Taiho Pharmaceutical, Ono Pharmaceutical, Bristol Myers Squibb, Towa Pharmaceutical, Boehringer Ingelheim; Financial Interests, Personal, Funding: MSD, AstraZeneca, Pfizer, Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly, Bristol Myers Squibb, Takeda; Financial Interests, Personal, Advisory Role: Eli Lilly. A. Tamiya: Financial Interests, Personal, Invited Speaker: AstraZeneca, Ono Pharmaceutical, MSD, Chugai Pharmaceutical, Novartis, Taiho Pharmaceutical, Boehringer Ingelheim, Kyowa Kirin, Eli Lilly, Daiichi Sankyo, Nihon-Kayaku, Pfizer, Amgen, Takeda, Merk BioPharma, Thermo Fischer, Bristol Myers Squibb; Financial Interests, Personal, Funding: Daiichi Sankyo, BeiGene, AstraZeneca. Y. Taniguchi: Financial Interests, Personal, Invited Speaker: AstraZeneca, Ono Pharmaceutical, MSD, Chugai Pharmaceutical. M. Oki: Financial Interests, Personal, Funding: AbbVie Inc., AstraZeneca, Chugai Pharmaceutical, Fujifilm Toyama Chemical Co Ltd., GSK K.K, Janssen Pharmaceutical, MSD, Ono Pharmaceutical, Parxel International Corporation, Pfizer, Sanofi; Financial Interests, Personal, Invited Speaker: AMCO, AstraZeneca, Canon Medical System Corporation, Chugai Pharmaceutical, Fujifilm Toyama Chemical Co Ltd., Kaneka Medix Corp., Merit Medical Japan K.K, Novartis, Olympus, Sanofi. M. Mori: Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, MSD, Eli Lilly, Novartis, Chugai Pharmaceutical, Taiho Pharmaceutical, Kyowa Kirin, Ono Pharmaceutical, Otsuka, Nihon-Kayaku, Pfizer, Daiichi Sankyo, Takeda, Shionogi; Financial Interests, Personal, Funding: Ono Pharmaceutical, Chugai Pharmaceutical, MSD, Delta-fly. Y. Koh: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical, Guardant Health, Amgen, Takeda, Tosoh Corporation; Financial Interests, Personal, Advisory Board: Tosoh Corporation; Financial Interests, Personal, Funding: Boehringer Ingelheim, AstraZeneca, Chugai Pharmaceutical, Tosoh Corporation, Daiichi Sankyo, Zeon Corporation, Amgen, Takeda. All other authors have declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract